Clinical Research Directory
Browse clinical research sites, groups, and studies.
Study Comparing ZG006 With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
Sponsor: Suzhou Zelgen Biopharmaceuticals Co.,Ltd
Summary
The main objective is to compare ZG006 with Investigator-Selected Chemotherapy on prolonging overall survival (OS).
Official title: A Multicenter, Randomized, Controlled, Open-Label Phase III Study Evaluating the Efficacy and Safety of ZG006 for Injection Compared With Investigator-Selected Chemotherapy in Participants With Relapsed Small Cell Lung Cancer
Key Details
Gender
All
Age Range
18 Years - 75 Years
Study Type
INTERVENTIONAL
Enrollment
420
Start Date
2025-12-12
Completion Date
2028-12
Last Updated
2026-01-05
Healthy Volunteers
No
Conditions
Interventions
ZG006
ZG006 will be administered as an intravenous (IV) infusion.
Topotecan
Topotecan will be administered per local standard of care
Locations (1)
Shanghai Chest Hospital
Shanghai, Shanghai Municipality, China